Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
Status:
Suspended
Trial end date:
2022-05-05
Target enrollment:
Participant gender:
Summary
This partially randomized phase I trial studies the side effects and best dose of disulfiram
when given together with chemotherapy in treating patients with a solid tumor that does not
respond to treatment (refractory) or pancreatic cancer that has spread to other places in the
body (metastatic) and to compare whether disulfiram and chemotherapy may reduce tumor induced
muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of
other cancers. Patients with metastatic cancer and weight loss sometimes are not able to
receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor
of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help
chemotherapy work better by making tumor cells more sensitive to the drug. Drugs used in
chemotherapy work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving chemotherapy with or without disulfiram is a better treatment for
refractory solid tumors or metastatic pancreatic cancer.